Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 72.39 percent increase over losses of $(1.63) per share from the same period last year. The company reported quarterly sales of $3.02 million which missed the analyst consensus estimate of $3.67 million by 17.74 percent. This is a 11.79 percent decrease over sales of $3.42 million the same period last year.